The earnings call highlighted significant progress in clinical trials, particularly in the TakeAim Lymphoma study and AML research, alongside improved financial figures. However, concerns about the limited cash runway and an uncertain regulatory environment introduce caution.

Company Guidance

During Curis' Second Quarter 2025 Business Update Call, several guidance metrics were provided. The company plans to enroll 30 to 40 additional patients in the TakeAim Lymphoma study over the next 12 to 18 months, aiming for NDA and EMA submissions. They anticipate initiating a proof-of-concept study for relapsed/refractory CLL with around 20 to 30 patients by year-end, expecting initial data by mid-2026. In AML, they plan a registrational study comparing emavusertib to gilteritinib. Financially, Curis reported a net loss of $8.6 million for Q2 2025, a decrease from $11.8 million in Q2 2024, with cash and equivalents of $10.1 million as of June 30, 2025. They completed a registered direct offering and private placement with net proceeds of approximately $6 million, extending their cash runway into Q1 2026.

Promising TakeAim Lymphoma Study Progress

The TakeAim Lymphoma study, evaluating emavusertib in combination with ibrutinib, is progressing well with expectations to support accelerated submissions in the U.S. and Europe after enrolling 30 to 40 additional patients.

Encouraging AML Study Results

The emavusertib study in relapsed/refractory AML showed a compelling 38% composite CR rate, significantly higher compared to gilteritinib's 21% in similar settings, indicating a promising novel mechanism of action.

Financial Improvement

Curis reported a net loss of $8.6 million for Q2 2025, a decrease from $11.8 million in Q2 2024, with reduced research and development as well as general and administrative expenses.

Curis (CRIS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CRIS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 12, 2025	2025 (Q3)	-0.58 / -	-1.7	―	―	―
Aug 05, 2025	2025 (Q2)	-1.36 / -0.68	-2.03	66.50% (+1.35)	―
May 06, 2025	2025 (Q1)	- / 1.25	-2.05	160.98% (+3.30)	―
Mar 31, 2025	2024 (Q4)	-1.11 / -1.25	-2.05	39.02% (+0.80)	―
Nov 14, 2024	2024 (Q3)	-1.83 / -1.70	-2.13	20.19% (+0.43)	―
Aug 01, 2024	2024 (Q2)	-1.79 / -2.03	-2.4	15.42% (+0.37)	―
May 07, 2024	2024 (Q1)	-2.04 / -2.05	-2.4	14.58% (+0.35)	―
Feb 08, 2024	2023 (Q4)	-2.12 / -2.03	-2.4	15.42% (+0.37)	―
Nov 02, 2023	2023 (Q3)	-2.33 / -2.13	-2.8	23.93% (+0.67)	―
Aug 03, 2023	2023 (Q2)	-2.36 / -2.40	-3.4	29.41% (+1.00)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CRIS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$1.60	$1.67	+4.37%
May 06, 2025	$2.45	$2.19	-10.61%
Mar 31, 2025	$2.32	$2.10	-9.48%
Nov 14, 2024	$3.93	$3.98	+1.27%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Curis Inc (CRIS) report earnings?

Curis Inc (CRIS) is schdueled to report earning on Nov 12, 2025, Before Open (Confirmed).

What is Curis Inc (CRIS) earnings time?

Curis Inc (CRIS) earnings time is at Nov 12, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CRIS EPS forecast?

CRIS EPS forecast for the fiscal quarter 2025 (Q3) is -0.58.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing